Загрузка...
Following in the footsteps of acute myeloid leukemia: Are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes?
For most patients with higher-risk myelodysplastic syndromes (HR-MDS) the hypomethylating agents (HMA) azacitidine and decitabine remain the mainstay of therapy. However, the prognosis mostly remains poor and aside from allogeneic hematopoietic stem cell transplantation no curative treatment options...
Сохранить в:
| Опубликовано в: : | Leuk Lymphoma |
|---|---|
| Главные авторы: | , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7670856/ https://ncbi.nlm.nih.gov/pubmed/32421403 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2020.1761968 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|